Nanobiotix's Hensify Earns CE Mark For Soft-Tissue Sarcoma

The CE mark will make Hensify nanoparticle radioenhancers available in 27 European countries. Hensify is the brand name for NBTXR3, an aqueous suspension of crystalline hafnium oxide nanoparticles, approved specifically for treating locally advanced soft-tissue sarcoma.

Approved stamp
• Source: shutterstock.com

Nanobiotix SA announced April 4 that its Hensify NBTXR3nanoparticle radioenchancer for locally advanced soft-tissue sarcoma has received a CE Mark to allow commercialization in 27 European countries.

Hensify is the brand name for NBTXR3 as approved for treating locally advanced soft-tissue sarcoma. NBTXR3 is an aqueous suspension of crystalline hafnium oxide nanoparticles designed to be injected directly...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

More from Business